Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

AstraZeneca (South Korea)

InstitutionResearch output, impact & collaborations

AstraZeneca (South Korea) is a research organisation in Seoul, KR. OpenAlex records 1,052 works and 54,221 citations for it. 560 researchers list it as their most recent affiliation.

1,052
Works
54,221
Citations
560
Researchers
47.5
Avg h-index

How has AstraZeneca (South Korea)'s publication output changed over time?

ScholarIQpublication output · 1996–2020

Output grew100% over the shown period — from 1 works in 1996 to 2 in 2020.

1
1
1
2
2
2
1
2
19962007201020152016201720182020

Who are the most-cited researchers behind AstraZeneca (South Korea)?

ScholarIQtop researchers by citations
1
Kenneth S. Thress · Lung Cancer Treatments and Mutations
108 works7,973 citations
2
David W. Boulton · Diabetes Treatment and Management
197 works7,268 citations

What are the most-cited papers on AstraZeneca (South Korea)?

ScholarIQmost cited works
A lexicon for endoscopic adverse events: report of an ASGE workshop
Peter B. Cotton, Glenn M. Eisen, Lars Aabakken, Todd H. Baron, Matt M. Hutter, Brian C. Jacobson, Klaus Mergener, Albert A. Nemcek, Bret T. Petersen, John L. Petrini, Irving M. Pike, Linda Rabeneck, Joseph Romagnuolo, John J. Vargo
Gastrointestinal Endoscopy. 20102,462 Citations
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard
Nature Medicine. 20151,558 CitationsOPEN ACCESS
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, James Chih‐Hsin Yang, J. Carl Barrett, Pasi A. Jänne
Journal of Clinical Oncology. 2016846 CitationsOPEN ACCESS
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard, James Yates, Zhenfan Yang, Dong‐Wan Kim, James Chih‐Hsin Yang, Mireille Cantarini, Kathryn Pickup, Angela Jordan, Mike Hickey, Matthew Grist, Matthew Box, Peter Johnström, Katarina Varnäs, Jonas Malmquist, Kenneth S. Thress, Pasi A. Jänne, Darren A.E. Cross
Clinical Cancer Research. 2016725 Citations
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
JAMA Oncology. 2018691 CitationsOPEN ACCESS

How much of the research on AstraZeneca (South Korea) is open access?

ScholarIQopen access share
67%OPEN ACCESS
Gold
8%
Green
17%
Hybrid
8%
Bronze
33%
Closed
33%

Related on ScholarIQ

Lung Cancer Treatments and Mutations
Top Topic
Cancer Immunotherapy and Biomarkers
Top Topic
Diabetes Treatment and Management
Top Topic
Asthma and respiratory diseases
Top Topic
HER2/EGFR in Cancer Research
Top Topic
Monoclonal and Polyclonal Antibodies Research
Top Topic
470M+ articles · free account